Tonix Pharmaceuticals (NASDAQ:TNXP) versus Silence Therapeutics (NASDAQ:SLN) Critical Survey

Silence Therapeutics (NASDAQ:SLN) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Institutional and Insider Ownership

98.7% of Silence Therapeutics shares are owned by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 4.1% of Silence Therapeutics shares are owned by insiders. Comparatively, 0.0% of Tonix Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Silence Therapeutics and Tonix Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-294.20%	-67.48%	-40.47%
Tonix Pharmaceuticals	-828.22%	-57.93%	-51.04%

Volatility and Risk

Silence Therapeutics has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals has a beta of 1.87, indicating that its share price is 87% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Silence Therapeutics and Tonix Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	2	0	5	0	2.43
Tonix Pharmaceuticals	1	0	2	0	2.33

Silence Therapeutics currently has a consensus target price of $32.60, indicating a potential upside of 345.96%. Tonix Pharmaceuticals has a consensus target price of $70.00, indicating a potential upside of 287.60%. Given Silence Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Silence Therapeutics is more favorable than Tonix Pharmaceuticals.

Earnings and Valuation

This table compares Silence Therapeutics and Tonix Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$43.26 million	N/A	-$45.31 million	($1.65)	-4.43
Tonix Pharmaceuticals	$10.09 million	15.70	-$130.04 million	($39.47)	-0.46

Silence Therapeutics has higher revenue and earnings than Tonix Pharmaceuticals. Silence Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Silence Therapeutics beats Tonix Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company’s priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company’s rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company’s infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.